Daniel Passeri
Chief Executive Officer at CUE BIOPHARMA, INC.
Net worth: 189 755 $ as of 2024-04-29
Profile
Daniel R.
Passeri is currently the Chief Executive Officer & Director at Cue Biopharma, Inc. He previously served as the Vice Chairman at Curis, Inc. from 2000 to 2016.
He also held the position of Vice Chairman at Xequel Bio, Inc. Additionally, he worked as the Director-Technology Management at Boehringer Mannheim Pharmaceuticals Corp.
from 1995 to 1997 and as the SVP-Corporate Development & Strategic Planning at Gene Logic, Inc. from 1997 to 2000.
In 2014 and 2015, he was the Head-Technology Management & Business Development at Genomic Medicine, Inc. Mr. Passeri obtained his graduate degree from Imperial College London and his undergraduate degree from Northeastern University.
He also holds a graduate degree from George Washington University Law School, which he received in 1994.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.28% | 2024-04-11 | 134,578 ( 0.28% ) | 189 755 $ | 2024-04-29 |
Daniel Passeri active positions
| Companies | Position | Start |
|---|---|---|
| CUE BIOPHARMA, INC. | Chief Executive Officer | 2016-07-31 |
Former positions of Daniel Passeri
| Companies | Position | End |
|---|---|---|
| CURIS, INC. | Chief Executive Officer | 2014-06-01 |
Genomic Medicine, Inc.
 Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Corporate Officer/Principal | 2015-05-31 |
Gene Logic, Inc.
 Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Corporate Officer/Principal | 2000-10-31 |
| Boehringer Mannheim Pharmaceuticals Corp. | Corporate Officer/Principal | 1997-02-28 |
Xequel Bio, Inc.
 Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Director/Board Member | - |
Training of Daniel Passeri
| Northeastern University | Undergraduate Degree |
| Imperial College London | Graduate Degree |
| George Washington University Law School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| CURIS, INC. | Health Technology |
| CUE BIOPHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Gene Logic, Inc.
Gene Logic, Inc. BiotechnologyHealth Technology Gene Logic, Inc. provides drug discovery and development services to pharmaceutical and biotechnology companies worldwide. The company operates in three segments: Genomics and Toxicogenomics Services, Preclinical Contract Research Services, and Drug Repositioning and Selection Services. Gene Logic was incorporated in 1994 and is headquartered in Gaithersburg, Maryland. | Health Technology |
| Boehringer Mannheim Pharmaceuticals Corp. | |
Xequel Bio, Inc.
Xequel Bio, Inc. Pharmaceuticals: MajorHealth Technology Xequel Bio, Inc. operates as a biopharmaceutical company. It develops drugs and medical applications for scar prevention, inflammation reduction, wound healing, and complex tissue regeneration. The company was founded by Gautam Sudhir Ghatnekar in 2005 and is headquartered in Mount Pleasant, SC. | Health Technology |
Genomic Medicine, Inc.
Genomic Medicine, Inc. Miscellaneous Commercial ServicesCommercial Services Part of GenoMed, Inc., Genomic Medicine, Inc. is a company that researches and studies disease causing genes. The company is based in St. Louis, MO. Genomic Medicine was acquired by GenoMed, Inc. on November 29, 2001 for $1.25 million. | Commercial Services |
- Stock Market
- Insiders
- Daniel Passeri
